시장보고서
상품코드
2150622

피부 마이크로바이옴 조절 시장 보고서 : 동향, 예측, 경쟁 분석(-2035년)

Skin Microbiome Modulation Market Report: Trends, Forecast and Competitive Analysis to 2035

발행일: | 리서치사: 구분자 Lucintel | 페이지 정보: 영문 150 Pages | 배송안내 : 3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

가격
PDF, Excel & 1 Year Online Access (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,850 금액 안내 화살표 ₩ 6,553,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF & Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,700 금액 안내 화살표 ₩ 9,053,000
PDF, Excel & 1 Year Online Access (Corporate License) help
PDF & Excel 보고서를 동일 기업 내 동일 국가의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,850 금액 안내 화살표 ₩ 11,959,000
PDF, Excel & 1 Year Online Access (Global License) help
PDF & Excel 보고서를 동일 기업(완전 자회사 포함)의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 금액 안내 화살표 ₩ 13,513,000
※ 부가세 별도
한글목차
영문목차

피부 마이크로바이옴 조절 시장

세계 피부 마이크로바이옴 조절 시장의 전망은 화장품, 의약품, 뉴트라슈티컬 시장의 기회를 배경으로 유망하게 평가되고 있습니다. 전 세계 피부 마이크로바이옴 조절 시장은 2027년 15억 달러에서 2035년에는 약 74억 달러에 달할 것으로 예상되며, 2027년부터 2035년까지 연평균 성장률(CAGR)은 18.1%를 기록할 전망입니다. 이 시장의 주요 성장 촉진요인으로는 천연 유래 스킨케어 제품에 대한 수요 증가, 피부 건강에 대한 인식 제고, 미생물군집을 기반으로 한 치료법의 확산 등이 꼽힙니다.

  • Lucintel사의 예측에 따르면, 제품 유형별로는 프로바이오틱스를 활용한 스킨케어 치료에 대한 소비자의 신뢰도가 높기 때문에 예측 기간 동안 프로바이오틱스 분야가 가장 높은 성장률을 보일 것으로 전망됩니다.
  • 최종 용도별로는 ‘클린 뷰티’에 대한 관심이 높아짐에 따라, 예측 기간 동안 화장품 분야가 가장 높은 성장률을 보일 것으로 예상됩니다.
  • 지역별로는 북미가 예측 기간 동안 가장 높은 성장률을 보일 것으로 전망됩니다. 이는 화장품 시장의 주요 지역에서 스킨케어 제품의 연구 개발(R&D)이 활발히 진행되고 있으며, 소비자 지출도 견조하기 때문입니다.

피부 마이크로바이옴 조절 시장의 새로운 동향

마이크로바이옴 시장은 실험적인 화장품에서 피부과, 퍼스널케어, 웰니스 분야의 증거 기반 제품으로 진화하고 있습니다. 2025년부터 2027년까지 각 기업은 마이크로바이옴 연구를 기반으로 한 안정적인 화장품 및 퍼스널케어 제품 개발에 주력할 전망입니다. 2030년까지 마이크로바이옴 기반 제품에 대한 규제 기준이 마련됨에 따라, 이러한 제품의 연구 개발에 대한 투자가 촉진될 것으로 예상됩니다. Lucintel사는 투자가 여드름, 피부 민감성, 스킨케어, 피부 장벽 기능 회복과 관련된 제품의 연구 개발에 집중될 것으로 예측하고 있습니다. 적극적인 파트너십을 통해 바이오기술과 퍼스널케어의 융합이 진행될 것입니다.

  • 임상 검증 : 화장품 및 퍼스널케어 업계에서는 피부 마이크로바이옴에 주목해 왔습니다. 2025년에 출시될 제품에는 피부 마이크로바이옴에 변화가 발생했음을 보여주는 증거가 포함될 것으로 예상됩니다. 2024년에 발표된 연구에 따르면, 마이크로바이옴에 관한 주장 중 증거로 뒷받침되는 것은 20% 미만이었습니다. 피부 마이크로바이옴의 변화에 관한 주장을 뒷받침하는 증거는 소비자의 구매 행동을 이끌고, 퍼스널케어 제품에 대한 규제를 촉진할 것으로 기대됩니다.
  • 맞춤형 제품 : 조사에 따르면, 가까운 시일 내에 피부 마이크로바이옴을 기반으로 한 맞춤형 제품이 등장할 전망입니다. 마이크로바이옴 기반 제품은 고객 유지율 향상과 평균 판매 가격 상승으로 이어질 것으로 예상됩니다.
  • 포스트바이오틱스 도입 : 2025년 마이크로바이옴 연구에 따르면, 포스트바이오틱스는 장벽 기능을 개선하고 피부 자극을 완화하는 것으로 나타났습니다. 바이오틱스에 비해 포스트바이오틱스의 제조 및 물류가 간소화되어 있다는 점이 스킨케어 시장에서 주목받고 있습니다. 대중 시장용 및 프리미엄 스킨케어 제품에 포스트바이오틱스를 배합함으로써 피부 마이크로바이옴을 조절하는 것이 가능해집니다.
  • 피부 트러블에 대한 집중 : 스킨케어에서 마이크로바이옴의 활용은 세안제나 토너에 그치지 않고 다른 제품으로 확대되고 있습니다. 여드름, 아토피 피부염 및 기타 피부 트러블을 대상으로 한 마이크로바이옴 기반 제품이 개발 중입니다. 아토피 피부염은 성인 인구의 10%에 영향을 미치고 있습니다. 이러한 제품에 대한 임상시험은 마이크로바이옴 기반 스킨케어 제품의 재구매를 촉진할 가능성이 있습니다.
  • 규제 당국의 표준화 : 규제 당국은 기업이 마이크로바이옴 기반 스킨케어 제품을 표기할 때의 지침을 발표했습니다. 규제 프레임워크의 표준화를 통해 기업들은 피부 마이크로바이옴을 조절하는 제품의 연구 개발에 투자할 수 있게 됩니다. 이 프레임워크는 피부 마이크로바이옴의 균형을 유지하는 제품 개발을 촉진하는 동시에, 피부 마이크로바이옴에 악영향을 미칠 가능성이 있는 제품의 개발을 억제하게 될 것입니다.

장벽 기능과 자극에 대한 안정성 및 효과를 입증한 제품이 스킨케어 시장을 주도하게 될 것입니다. 제품 처방의 개선과 혁신을 통해 마이크로바이옴 스킨케어 제품은 클렌징이나 토너에 그치지 않고 다양한 제품에 적용되고 있습니다. 검증 연구와 임상시험을 통해 피부 마이크로바이옴에 의해 조절된 제품의 안전성과 유효성이 입증될 것입니다. 생명공학 기업, 스킨케어 기업, 피부과 전문의 간의 협력을 통해 스킨케어 제품에 피부 마이크로바이옴을 통합하는 움직임이 가속화될 것입니다.

피부 마이크로바이옴 조절 시장의 최근 동향

조절된 피부 마이크로바이옴을 포함한 스킨케어 제품 및 성분 시장은 보조 처방이나 포스트바이오틱 플랫폼, 임상 데이터를 갖춘 제품이 시장에 등장함에 따라 향후 몇 년간 성장할 것으로 예상됩니다. Lucintel에 따르면, 스킨케어 시장은 성장을 지속할 것이며, 신규 성분에 대한 의존도는 낮아지고 규제 준수가 더욱 중요시될 것입니다.

  • 임상 검증 : 2025년 1월, 한 기업이 마이크로바이옴을 지원하는 스킨케어 제품에 대한 12주간의 임상시험을 후원했습니다. 검증 결과와 이를 뒷받침하는 데이터가 늘어남에 따라, 스킨케어 제품은 피부 건강에 미치는 영향에 대해 더욱 강력한 효능을 내세울 수 있게 되어, 단순한 미용상의 이점을 넘어서는 제품이 될 것입니다.
  • 포스트바이오틱스 기술 : 2025년 3월, 한 스킨케어 원료 플랫폼 공급업체가 3종류의 포스트바이오틱스 분획을 포함하고 민감성 피부용 스킨케어 제품에 배합된 플랫폼을 출시했습니다.
  • 추가 제휴 : 2025년 5월, 한 스킨케어 제품 제조사와 생명공학 기업이 미생물 대사산물을 함유한 제품을 개발하기 위해 여러 건의 제휴 계약을 체결했습니다.
  • 미생물군집 생산능력 : 2025년 8월, 유럽의 한 생명공학 기업이 1,500제곱미터 규모의 발효 시설을 개장했습니다. 이 시설에서는 화장품 원료가 제조됩니다. 그 밖의 미생물군집 원료도 더 대규모로 생산되어 신뢰성 향상과 비용 절감이 도모될 것입니다.
  • 마이크로바이옴 관련 기준 : 살아있는 미생물과 포스트바이오틱스(postbiotics)의 구분이 더욱 명확해졌으며, 2025년 10월에 마이크로바이옴에 관한 표시 지침이 공표되었습니다. 업계는 이러한 명확화의 혜택을 받게 되며, 기업들은 포스트바이오틱스나 미생물을 함유한 제품에 대해 근거 없는 효능 표기를 할 수 없게 됩니다. 이 기준과 명확화를 통해 기업이 특정 효능 표기를 입증할 수 있는 제품 개발이 가속화되고, 근거 없는 효능 표기를 하는 기업은 제한받게 될 것입니다. 피부 마이크로바이옴을 조절하는 제품은 특정 효능을 내세우는 스킨케어 제품의 혁신을 촉진할 것입니다.

미생물군집 스킨케어 분야에서 구체적인 효능 표기를 가능하게 하는 기술이나 제품을 개발한 기업에 투자가 집중될 것입니다. 규제 및 기술적 진보에 힘입어 맞춤형 스킨케어 제품의 상용화가 가능해지며, 피부의 미생물군집을 조절할 수 있게 될 것입니다.

목차

제1장 주요 요약

제2장 시장 개요

제3장 시장 동향과 예측 분석

제4장 세계의 피부 마이크로바이옴 조절 시장 : 제품 유형별

제5장 세계의 피부 마이크로바이옴 조절 시장 : 성분별

제6장 세계의 피부 마이크로바이옴 조절 시장 : 용도별

제7장 세계의 피부 마이크로바이옴 조절 시장 : 최종 용도별

제8장 지역별 분석

제9장 북미의 피부 마이크로바이옴 조절 시장

제10장 유럽의 피부 마이크로바이옴 조절 시장

제11장 아시아태평양의 피부 마이크로바이옴 조절 시장

제12장 기타 지역의 피부 마이크로바이옴 조절 시장

제13장 경쟁 분석

제14장 기회와 전략 분석

제15장 밸류체인 전체의 주요 기업 개요

제16장 부록

KSM

Skin Microbiome Modulation Market

The future of the global skin microbiome modulation market looks promising with opportunities in the cosmetic, pharmaceutical, and nutraceutical markets. The global skin microbiome modulation market is expected to reach an estimated $7.4 billion by 2035 from $1.5 billion in 2027 with a CAGR of 18.1% from 2027 to 2035. The major drivers for this market are the increasing demand for natural skincare products, the rising awareness about skin health, and the growing adoption of microbiome-based treatments.

  • Lucintel forecasts that, within the product type category, probiotics is expected to witness the highest growth over the forecast period due to high consumer trust in probiotic skin treatments.
  • Within the end use category, cosmetics is expected to witness the highest growth over the forecast period due to increasing interest in clean beauty.
  • In terms of regions, North America is expected to witness the highest growth over the forecast period due to leading markets for cosmetics have advanced skin care product research and development (R&D) and strong consumer spending.

Emerging Trends in Skin Microbiome Modulation Market

The microbiome market is evolving from experimental cosmetics into evidence-based offerings in dermatology, personal care and wellness. Companies will focus on forming stable cosmetic and personal care products based upon microbiome research from 2025 to 2027. Prior to 2030, criteria for regulation of microbiome based products is expected to encourage investment in research and development of such products. Lucintel predicts investment will focus on research and development of products related to acne, skin sensitivity, skin care and skin barrier repair. Willful partnerships will integrate biotechnology and personal care.

  • Clinical Validation: There has been a focus on the microbiome of the skin in the cosmetic and personal care industry. Products launched in 2025 are expected to include evidence of a change in skin microbiome. A study published in 2024 reported less than 20% of microbiome claims were supported by evidence. It is expected that evidence supporting claims related to changes in skin microbiome will help guide consumer purchasing and support regulation of personal care products.
  • Personalized Products: From research, it appears that in the near future products personalized based upon the microbiome of the skin will be available. It is expected that microbiome based products will enhance retention rates and increase the average selling price.
  • Adoption of Postbiotics: The 2025 microbiome study showed postbiotics improved barrier function and reduced skin irritation. Simplification of the production and logistics of postbiotics compared to biotics has gained focus in the skincare market. Mass market and premium skincare products can incorporate postbiotics to modulate the skin microbiome.
  • Focus on Skin Conditions: The microbiome in skincare is expanding into other products beyond cleansers and toners. Microbiome-based products for acne, atopic dermatitis and other skin conditions are under development. Atopic dermatitis affects 10% of the adult population. Clinical trials for these products can increase repeat purchase microbiome-based skincare products.
  • Standardization By Regulators: Regulatory agencies have issued guidance to help companies label microbiome-based skincare products. Standardization of regulatory frameworks will allow companies to invest in research and development of products to modify the skin microbiome. The frameworks will encourage companies to develop products to maintain the skin microbiome in balance and discourage companies from developing products that may negatively affect the skin microbiome.

Products that demonstrate stability and benefits for barrier function and irritation will dominate the skincare market. Improvement in product formulation and innovation has enabled microbiome skincare products to be integrated into various products beyond cleansers and toners. Validation studies and clinical trials will demonstrate the safety and efficacy of products modified by the skin microbiome. Collaborations among biotech companies, skincare companies and dermatologists will accelerate the integration of the skin microbiome in skincare products.

Recent Developments in the Skin Microbiome Modulation Market

The market for skincare products and ingredients containing modulated skin microbiomes is expected to grow over the next several years as products containing supporting formulations, postbiotic platforms and clinical data come to market. According to Lucintel, the skincare market will continue to grow and be less reliant on novel ingredients, and more on regulatory compliance.

  • Clinical Validation: In January 2025, a company sponsored a 12-week clinical study of a microbiome-supporting skincare product. With greater validation and supporting data, skincare products will be able to make stronger claims regarding their impact on skin health and move beyond cosmetic benefits.
  • Postbiotic Technology: In March 2025, a suppliers of skincare ingredient platforms launched a platform containing three postbiotic fractions and formulating for skincare products for sensitive skin.
  • Additional Collaborations: In May 2025, a skincare product company and a biotechnology company entered into multiple collaborations to develop products containing microbial metabolites.
  • Microbiome Capacity: A European biotech company opened a 1,500 square-meters facility for fermentation in August 2025. The facility will manufacture cosmetic ingredients. Other microbiome ingredients will be produced at larger scales, improving reliability and reducing costs.
  • Microbiome Standards: Live microorganisms and post microorganisms (postbiotics) are further differentiated, and guidance on microbiome claims is published in October 2025. The industry will benefit from the clarifications, and companies will no longer be able to make unsubstantiated claims on products containing postbiotics and/or microorganisms. The standard and clarifications will accelerate the development of products which enable companies to substantiate specific claims and limit companies making unsubstantiated claims. Products which modify the skin microbiome will foster innovation in claim specific skincare products.

Investment will be directed toward companies which developed technologies and products that enable specific claims in the microbiome skincare space. Regulatory and technological advances will allow for the commercialization of personalized skincare products and modulate the skin microbiome.

Strategic Growth Opportunities in the Skin Microbiome Modulation Market

Lucintel has released key insights into the emerging skin microbiome modulation market. This report indicates an evolution from the specialized skincare market, toward the clinically-supported consumer health market, by 2026. Trends in the ability to sequence the skin microbiome more precisely and the demand for repair of functional lipid barriers, are some of the factors creating new market opportunities. According to Lucintel, the recent focus on premium and medical dermatologic skincare is expected to create new market opportunities.

  • Dermatologic Therapeutics: From a product development perspective, the Skin Microbiome offers opportunities for the creation of prescription-like skincare products for the management of conditions such as acne and atopic dermatitis, among others. Galderma's focus on science and innovation in the Dermatology space has shown to be profitable. Likewise, other Skin Microbiome modulators may find success in the skincare space beyond simple moisturization.
  • Premium Skincare: The Skin Microbiome offers many opportunities for skincare products focused on barrier function and skin sensitivity. The recently published financial results of L'Oreal for the year 2024, point toward the growth of the Dermatologic Cosmetics segment of the company. New innovations by skincare companies that focus on research and development will help achieve clinical endpoints and shift the Skin Microbiome modulators beyond simple moisturization.
  • Automated Assessments and Tailored Therapies: The American Academy of Dermatology (AAD) represented 20,000+ members in 2025. The presence of this professional body provides opportunity for standardized assessment. In the next 3-5 years, the presence of biomarkers will lead to subscriptions, clinic partnerships and increased user retention.
  • Asia-Pacific: Countries like India, Southeast Asia and South Korea, have large populations with skin conditions exacerbated by pollution and benefit from our product offerings due to pervasive e-commerce. The Indian beauty and personal care market was valued at $28 billion in 2025. Since many of these countries are historically exporting commodities, we expect supplier/partner preference for locally produced offerings.
  • The Skin Microbiome: Preservatives, surfactants and other ingredients that maintain the microbiome and are of suitable safety and efficacy will gain approval by regulatory bodies. The CosIng database has >30,000 ingredients. With these, developers will create products and feel more confident in the compatibility and shelf stability.

It is our belief that biology-backed, normal-range products will garner the most interest and be the fastest growing. This will be the case if products fulfill a primary need to improve the condition and appearance of skin. Trust of the medical community will be of utmost importance.

Skin Microbiome Modulation Market Drivers and Challenges

The evolution of the microbiome-based skin care product category is driven by several overlapping factors, including changes in the law, the economy, and science and technology. Growing attention to the skin barrier and the role of microbiome balance has led to the development of skin care products focused on the skin microbiome. The rise in the convergence of disciplines has inspired the development of a range of products. Other forces, such as changing regulations and the economy, influence the type of ingredients and packaging that may be used in the products. The results of Lucintel's analysis indicate that the future of the microbiome-based skin care products category is bright; however, the company recognizes that there are a number of barriers to the wide-scale adoption of these products, including traditional barriers such as consumer acceptance, regulatory approval and strict liability.

The factors responsible for driving this market include :

  • Growing Customer Interest: There is growing customer interest in products that strengthen the skin barrier and/or reduce skin irritation and help to address conditions such as acne and other instances of skin dryness and/or sensitivity and inflammation. Rather than relying on products that contain traditional, more active ingredients. Customer interest continues to grow for products that contain microbiome friendly ingredients and/or other ingredients that strengthen the skin barrier. The interest in products that contain microbiome friendly ingredients has expanded to over-the-counter (OTC) products, as well as professional and medical products. In 2025, the preventative skincare market continued to gain customer interest and grow, as evidenced by the increasing demand for products that contain prebiotics, probiotics and/or postbiotics, as well as other skincare products that contain gentle, or/and, sensitive skin formulas. This focus on preventative skincare has resulted in skincare product manufacturers investing in a variety of activities, including educating customers and the general public, and/or conducting clinical trials to develop and introduce new, and/or differentiated, skincare products to the marketplace. It is expected that during the next 3 to 5 years, the skincare market would continue to expand, as the general public continues to become more aware of skincare and as more skincare product outlets (i.e. dermatology clinics, pharmacies and online retailers) carry and sell skincare products.
  • Innovation in Biotechnology: Advances in biotechnology and related sciences have enhanced the ability of firms to identify and/or develop skin microbes associated with healthy skin. The advances in science and related technologies have allowed firms to more efficiently develop skincare and other products for customers with various skin conditions and types. In 2025, skin microbiome testing and research concentrated on and analyzed smaller (but more representative) sample sizes of skin microbiome genetic markers, as compared to skin microbiome tests and research that was conducted in earlier years. As a result of this research, and other related scientific and technological advancements, the skincare product market is expected to continue to shift toward more individualized and/or personalized skincare products, as well as away from more broad and/or general skincare products.
  • Clinical Validation and Product Innovation: More clinically relevant data is directing the development of more customized skincare products. The use of various barrier-supportive lipids and other postbiotic metabolites is becoming more common to adjust the skin microbiome. In the next few years, the skincare market will likely see more clinical studies on the efficacy of skincare products. These studies will help provide more data on skin conditions, such as levels of skin hydration, inflammation, and lesion counts. As the certainty and availability of clinical studies increase, skincare product innovations will likely allow for the clear distinction and positioning of skincare products based on their therapeutic and cosmetic benefits and uses.
  • Sustainability and Natural Ingredient Preference: More sustainable production and packaging methods will likely become more common in the skincare market. These changes will encourage more responsible sourcing of raw materials and packaging and help differentiate lower-end skincare products. The emphasis on more sustainable production will likely create changes in skincare product formats and alter supply and bioprocessing to meet consumer needs and desires. In the next several years, ongoing changes in consumer values and preferences should accelerate improvements in overall skincare product sustainability.
  • Personalized Skincare Products and Services: Are on the rise, allowing dermatology, aesthetic, and telehealth industries to expand their offerings. Incorporation of the microbiome into skincare products is becoming more common. Microbiome diagnosis in conjunction with barrier function and inflammation may assist healthcare providers in developing individualized skincare plans. Throughout 2025, skincare plans focused on incorporating questions and assessment into plans in an effort to create personalized plans based on biology and/or behavior. Barriers to entry for skincare plans remained low; however, integration of medical diagnostics and regulation of skincare products may provide a competitive edge. During the next three to five years, personalized skincare plans may become the norm.

The challenges facing this market include:

  • Variability: There are numerous factors that impact the skin microbiome including, sex, age, genetics, geography, climate, medications, and personal care products. Different labs may use different methods to analyze and interpret samples, resulting in variability and an inability to consistently reproduce similar studies. In 2025, comparative research relied on numerous statistical and analytical methods. This made it difficult to evaluate the efficacy of products containing microbiome-based ingredients. There is a need for consistent and reliable research to create standardization in this market. During the next three to five years, reliance on standardized research may allow for companies to make valid claims.
  • Uncertainty with Respect To Regulations and Claims: There are different legal requirements for products categorized as cosmetics as opposed to drugs, biologics and supplements. The same is true for the types of claims that may be made for a product. Claims for products that may alter the immune system or may have a role in the restoration of various microorganisms may result in negative action by regulatory authorities. The consequence of this may be that a product may not be labeled or marketed in a manner that communicates general benefits to consumers, i.e., moisturizing claims. Currently, there is ambiguity and uncertainty regarding what types of claims may be allowable for therapeutic cosmetic products. Manufacturers wishing to sell products in multiple countries may be required to modify labels and claims for various markets.
  • Barriers To Safety and Commercialization: The use of various biologically active ingredients, including microorganisms, may result in safety and efficacy concerns if the product is not properly stored, preserved and packed. Interactions between ingredients in the formulation may compromise the safety of the product. The practicality of manufacturing a product that contains live microorganisms may result in the use of a postbiotic or prebiotic in the product. In addition, there may be reluctance on the part of consumers to pay a price that justifies the development of the product. This is particularly true in the absence of long term data concerning the safety of the product. There are a number of barriers that must be overcome, e.g. the safety and commercialization of a product that uses microorganisms. These barriers may also constrain the development of other biologically active products.

The market for products and services modifying the skin microbiome will continue expanding. This is the case not only because several developments in the biotech sector and consumer-centric services will overlap, but also because focus on environmental friendliness and innovation in product and process technology will also converge. However, it is expected that the further development of the microbiome modulation field will occur in a non-harmonious manner. The resistance of certain members of the skin microbiome to modification, as well as the variability of the skin microbiome within an individual, will make it difficult to develop products that modify the skin microbiome to address several dermatological conditions. Because of the high costs of developing microbiome modulation-based products and the existing regulatory challenges in the cosmetics sector, it is expected that companies with sufficient resources, strong clinical evidence, and an understanding of the microbiome will dominate the market. During the next five years, products and services based on the skin microbiome will be more targeted to dermatological conditions for which clinically relevant data are available.

List of Skin Microbiome Modulation Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies skin microbiome modulation market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the skin microbiome modulation market companies profiled in this report include-

  • Evonik Industries
  • Givaudan
  • Amorepacific
  • Shiseido Group
  • Lallemand

Skin Microbiome Modulation Market by Segment

The study includes a forecast for the global skin microbiome modulation market by product type, ingredient, application, end use, and region.

Skin Microbiome Modulation Market by Product Type [Value ($B) from 2019 to 2035]:

  • Probiotics
  • Prebiotics
  • Postbiotics
  • Symbiotics

Skin Microbiome Modulation Market by Ingredient [Value ($B) from 2019 to 2035]:

  • Lactobacillus Stains
  • Bifidobacterium Strains
  • Fermented Plant Extract
  • Yeasts
  • Others

Skin Microbiome Modulation Market by Application [Value ($B) from 2019 to 2035]:

  • Acne
  • Anti-Aging
  • Atopic Dermatitis
  • Psoriasis
  • Sensitivity
  • Others

Skin Microbiome Modulation Market by End Use [Value ($B) from 2019 to 2035]:

  • Cosmetics
  • Pharmaceuticals
  • Nutraceuticals

Skin Microbiome Modulation Market by Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Skin Microbiome Modulation Market

The skin microbiome modulation market is evolving from the use of probiotics to other microbiome modulators such as postbiotics and prebiotics. This market is expected to gain traction in the mid-2020s. It is expected that in the mid-2020s, there will be greater regulatory and financial investment in the strain characterization of microorganisms. According to Lucintel, until new advancements are made in this space, companies will primarily rely on their own internal research to develop products in this area.

  • United States: Under the Modernization of Cosmetics Regulations, the U.S. Food and Drug Administration (FDA) has implemented a system to require cosmetic companies to register their facilities and list the cosmetic products they manufacture and/or distribute. From December 2024, cosmetic companies will also be required to report adverse event reports for cosmetic products to FDA. These regulatory requirements are likely to stimulate the development of advanced microbiome-based cosmetic products, and microbiome-based personal care products in the U.S. between 2025 and 2030.
  • China: In 2025, L'Oreal and the Zhangjiang Group entered into an agreement to establish the Shanghai International Consumer Products Innovation Center. The Center is expected to stimulate R&D and commercialization of innovative beauty and personal care products, and related microbiome technologies. China is also expected to promote research on microbiome products and stimulate the introduction of related products in the Chinese market within the next 3-5 years.
  • Germany: According to Beiersdorf's 2025 report, microbiome research, additionally strengthened through their 2022 acquisition of a majority stake in S-Biomedic (a company founded in 2018), will continue to be one of their key strategic research platforms. Molecular research on live (or recently cultured) microorganisms, including those found on and in the body, is integrated in Beiersdorf's research and development efforts to build a range of high-end skincare products.
  • India: The Biotechnology Industry Research Assistance Council (BIRAC) of the Department of Biotechnology (DBT) of India, in conjunction with other organizations, extended grants in 2024-2025 to biotechnology startups. Among the grants, albeit few, were awards for development of microbiome-based products for healthcare. It is expected that these efforts will promote microbiome research in India.
  • Japan: Shiseido 2025 report indicated that they would continue investment in 'skin science' and 'personalized beauty' research. 2024 launch of 'ULTIMUNE The Serum' reflected the research emphasis. 'Consumer insights' together with advancing research on microbiome, is expected to result in the launch of a series of new high-end skincare products.

Features of the Global Skin Microbiome Modulation Market

  • Market Size Estimates: skin microbiome modulation market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: skin microbiome modulation market size by various segments, such as by product type, ingredient, application, end use, and region in terms of value ($B).
  • Regional Analysis: skin microbiome modulation market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different product types, ingredients, applications, end uses, and regions for the skin microbiome modulation market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the skin microbiome modulation market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the skin microbiome modulation market by product type (probiotics, prebiotics, postbiotics, and symbiotics), ingredient (lactobacillus stains, bifidobacterium strains, fermented plant extract, yeasts, and others), application (acne, anti-aging, atopic dermatitis, psoriasis, sensitivity, and others), end use (cosmetics, pharmaceuticals, and nutraceuticals), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Skin Microbiome Modulation Market by Product Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Product Type
  • 4.3 Probiotics : Trends and Forecast 2019 to 2035
  • 4.4 Prebiotics : Trends and Forecast 2019 to 2035
  • 4.5 Postbiotics : Trends and Forecast 2019 to 2035
  • 4.6 Symbiotics : Trends and Forecast 2019 to 2035

5. Global Skin Microbiome Modulation Market by Ingredient

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Ingredient
  • 5.3 Lactobacillus Stains : Trends and Forecast 2019 to 2035
  • 5.4 Bifidobacterium Strains : Trends and Forecast 2019 to 2035
  • 5.5 Fermented Plant Extract : Trends and Forecast 2019 to 2035
  • 5.6 Yeasts : Trends and Forecast 2019 to 2035
  • 5.7 Others : Trends and Forecast 2019 to 2035

6. Global Skin Microbiome Modulation Market by Application

  • 6.1 Overview
  • 6.2 Attractiveness Analysis by Application
  • 6.3 Acne : Trends and Forecast 2019 to 2035
  • 6.4 Anti-Aging : Trends and Forecast 2019 to 2035
  • 6.5 Atopic Dermatitis : Trends and Forecast 2019 to 2035
  • 6.6 Psoriasis : Trends and Forecast 2019 to 2035
  • 6.7 Sensitivity : Trends and Forecast 2019 to 2035
  • 6.8 Others : Trends and Forecast 2019 to 2035

7. Global Skin Microbiome Modulation Market by End Use

  • 7.1 Overview
  • 7.2 Attractiveness Analysis by End Use
  • 7.3 Cosmetics : Trends and Forecast 2019 to 2035
  • 7.4 Pharmaceuticals : Trends and Forecast 2019 to 2035
  • 7.5 Nutraceuticals : Trends and Forecast 2019 to 2035

8. Regional Analysis

  • 8.1 Overview
  • 8.2 Global Skin Microbiome Modulation Market by Region

9. North American Skin Microbiome Modulation Market

  • 9.1 Overview
  • 9.2 North American Skin Microbiome Modulation Market by Product Type
  • 9.3 North American Skin Microbiome Modulation Market by End Use
  • 9.4 The United States Skin Microbiome Modulation Market
  • 9.5 Canadian Skin Microbiome Modulation Market
  • 9.6 Mexican Skin Microbiome Modulation Market

10. European Skin Microbiome Modulation Market

  • 10.1 Overview
  • 10.2 European Skin Microbiome Modulation Market by Product Type
  • 10.3 European Skin Microbiome Modulation Market by End Use
  • 10.4 German Skin Microbiome Modulation Market
  • 10.5 French Skin Microbiome Modulation Market
  • 10.6 Italian Skin Microbiome Modulation Market
  • 10.7 Spanish Skin Microbiome Modulation Market
  • 10.8 The United Kingdom Skin Microbiome Modulation Market

11. APAC Skin Microbiome Modulation Market

  • 11.1 Overview
  • 11.2 APAC Skin Microbiome Modulation Market by Product Type
  • 11.3 APAC Skin Microbiome Modulation Market by End Use
  • 11.4 Chinese Skin Microbiome Modulation Market
  • 11.5 Indian Skin Microbiome Modulation Market
  • 11.6 Japanese Skin Microbiome Modulation Market
  • 11.7 South Korean Skin Microbiome Modulation Market
  • 11.8 Indonesian Skin Microbiome Modulation Market

12. ROW Skin Microbiome Modulation Market

  • 12.1 Overview
  • 12.2 ROW Skin Microbiome Modulation Market by Product Type
  • 12.3 ROW Skin Microbiome Modulation Market by End Use
  • 12.4 Middle Eastern Skin Microbiome Modulation Market
  • 12.5 South American Skin Microbiome Modulation Market
  • 12.6 African Skin Microbiome Modulation Market

13. Competitor Analysis

  • 13.1 Product Portfolio Analysis
  • 13.2 Operational Integration
  • 13.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Growth Opportunity Analysis
    • 14.2.1 Growth Opportunity by Product Type
    • 14.2.2 Growth Opportunity by Ingredient
    • 14.2.3 Growth Opportunity by Application
    • 14.2.4 Growth Opportunity by End Use
  • 14.3 Emerging Trends in the Global Skin Microbiome Modulation Market
  • 14.4 Strategic Analysis
    • 14.4.1 New Product Development
    • 14.4.2 Certification and Licensing
    • 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

  • 15.1 Competitive Analysis Overview
  • 15.2 Evonik Industries.
    • Company Overview
    • Skin Microbiome Modulation Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.3 Givaudan
    • Company Overview
    • Skin Microbiome Modulation Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.4 Amorepacific
    • Company Overview
    • Skin Microbiome Modulation Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.5 Shiseido Group
    • Company Overview
    • Skin Microbiome Modulation Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.6 Lallemand
    • Company Overview
    • Skin Microbiome Modulation Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.7 DSM-Firmenich
    • Company Overview
    • Skin Microbiome Modulation Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.8 Unilever plc
    • Company Overview
    • Skin Microbiome Modulation Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.9 BASF SE
    • Company Overview
    • Skin Microbiome Modulation Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.10 Colgate-Palmolive Company
    • Company Overview
    • Skin Microbiome Modulation Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.11 Johnson & Johnson
    • Company Overview
    • Skin Microbiome Modulation Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

16. Appendix

  • 16.1 List of Figures
  • 16.2 List of Tables
  • 16.3 Research Methodology
  • 16.4 Disclaimer
  • 16.5 Copyright
  • 16.6 Abbreviations and Technical Units
  • 16.7 About Us
  • 16.8 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기